RECCE PHARMACEUTICALS LTD — Director's Dealing 2019

Mar 6, 2019

Change of Director’s Interest Notice

SYDNEY, Australia, 7 March 2019: Recce Pharmaceuticals Ltd (ASX: RCE) ( Company ), the Company developing a new class of synthetic antibiotics, is pleased to advise that Executive Director, James Graham, has purchased 650,000 fully paid ordinary shares in the Company on the market for a total consideration of approximately $100,460 (an average price of $0.1546 per share).

A Change of Director’s Interest Notice is attached. The purchase of 650,000 fully paid ordinary shares is in line with Mr Graham’s commitment and support to the Company’s ongoing strategy and objectives.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.

==> picture [595 x 99] intentionally omitted <==

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd ABN 73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

the director for the purposes of section	205G of the Corporations Act.
Name of Director	James Hamilton Bray Graham
Date of last notice	9 March 2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct or indirect interest	Indirect Interest	Indirect Interest	Indirect Interest	Indirect Interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving riseto the relevant interest.		Bulleen Pty Ltd
Date of change		Date of Trade:1 March 20194 March 20195 March 20196 March 2019
No. of securities held prior tochange		Direct Interest:1. 1,868,601 ordinary shares2. 389,712 Class B Performance Shares3. 389,712 Class C Performance Shares4. 389,712 Class D Performance SharesIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 1,781,250 ordinary shares
		2. 356,250 Class B Performance Shares3. 356,250 Class C Performance Shares
		4. 3	56,250 Class D	Performance S	hares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Fully Paid Ordinary Shares
Number acquired	650,000 ordinary shares
Number disposed	N/A
Value/Consideration	$0.1546 per Ordinary Share (Average Price)
Note: If consideration is non-cash, provide details andestimated valuation	Total Consideration: approximately $100,460
No. of securities held after change	Direct Interest:
	1. 1,868,601 ordinary shares
	2. 389,712 Class B Performance Shares
	3. 389,712 Class C Performance Shares
	4. 389,712 Class D Performance Shares
	Indirect Interest:
	Mr. James Graham <J Graham Family A/c>
	1. 1,781,250 ordinary shares
	2. 356,250 Class B Performance Shares
	3. 356,250 Class C Performance Shares
	4. 356,250 Class D Performance Shares
	Bulleen Pty Ltd
	1. 650,000 ordinary shares
Nature of change	On-market trade.
Example: on-market trade, off-market trade, exercise
of options, issue of securities under dividend
reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which interest related prior to	N/A
change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an estimated valuation

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change	N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3